Regarding chemotherapy, combining ADCs with traditional chemotherapeutic drugs also shows complementary advantages: The Phase II TEAL study demonstrated that T-DM1 combined with lapatinib and albumin-bound paclitaxel significantly increased the pathological CR rate in patients, exhibiting a stronger tumor-shrinking effect compared to traditional “dual antibody + chemotherapy” regimens[152]. Here, ALB is linked to neoplasm.